Clinical Trial Failure Risk: The primary risk for a clinical-stage company like CNTX is that its product candidates, such as ONA-XR, fail to achieve favorable results in clinical trials, which would halt development and severely impact the company's prospects and valuation.

Regulatory Approval Uncertainty Risk: Even with successful clinical trials, there is no guarantee that regulatory authorities like the FDA will approve their product candidates for commercialization, leading to potential delays, additional costly studies, or outright rejection.

Capital and Funding Adequacy Risk: Context Therapeutics has a history of operating losses and will require significant additional capital to complete development and commercialization of its product candidates, which may not be available on favorable terms or at all, potentially forcing the company to delay or discontinue development programs.